RESI Is Now Offering Investor Spotlight Package

22 Feb

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-newThe Redefining Early Stage Investments Conference (RESI) is now offering an Investor Spotlight Package, which for the first time allows investor firms to be featured and stand out from more than 300+ investors attending the 2018 RESI Toronto conference.

Investor Spotlight Package includes the following:

  • A Dedicated, Branded Partnering Table in the partnering forum. This is your table and a great opportunity to have an established highly visible spot in the partnering room where companies can meet you. The table will be branded by your firm’s logo and name.
  • Featured Investor Profile on the RESI website, in the hard copy and digital version of the RESI Conference Program Guide, and in the RESI Partnering System – making your investment mandate visible to RESI attendees.
  • Special mailings of your firm’s profile to all RESI Companies that are a fit for your firm’s mandate.

To qualify you must be:

  • Investment staff involved directly in an early-stage life science or healthcare venture capital or private equity fund.
  • Investment staff at a family office or private wealth fund that invests in life sciences.
  • External innovation, early-stage partnering or in-licensing staff from major corporations in the life science and healthcare industry.
  • Active life science angels or executive staff at angel organizations that invest in early-stage life science companies.
  • Investment staff and executives at nonprofit organizations, venture philanthropy/impact investment firms or patient groups that provide funding to startup companies.
  • Senior management or investment staff from a pension, endowment, foundation or employee benefit plan currently invested in life sciences.

For more information, please contact us

at 617-600-0668 or resi@lifesciencenation.com

22

A Canadian Fundraising CEO’s Success at RESI

22 Feb

Anton Neschadim

An interview with Anton Neschadim, CEO, ImmunoBiochem
– By Chris Cummings, Senior Marketing Manager, LSN

Chris Cummings

Chris Cummings: What is your background, and how long have you been working in the life science space?

Anton Neschadim: I am a scientist-entrepreneur. I have a very deep, multi-disciplinary science background that I ultimately combined with a business degree, all from the University of Toronto. I am a lateral thinker, and as such always strived to be a subject-matter expert across multiple areas. And so, contrary to the traditional path of specialization in academia, I wanted to become a problem solver and innovator, and sought to master additional disciplines with every degree – chemistry, physics, immunology, cancer research, regenerative medicine. I believe that being able to draw on knowledge from multiple disciplines is key to generating creative insights. I transitioned into industry eight years ago, in the final year of my PhD, and took up a drug development role in a biologics program, while continuing to work in an academic lab evenings and weekends to amass more than 25 manuscripts and patents. Three years ago, I have focused on leading ImmunoBiochem with an exciting novel biologics program.

Chris Cummings: Are you currently fundraising? What previous financing or milestones has your company achieved (that you can disclose)?

Anton Neschadim: We are always fundraising, and are targeting to close another round led by current investors and partners in March. Our first deal was with one of the RESI sponsors and helped us develop fully-human antibody molecules for our lead target, and the subsequent angel-led round allowed us to develop a lead that we showed to be both efficacious and safe in preclinical animal tumor models. This new round will take our lead molecule into large animal studies, but we are eager to get into the clinic and are looking for additional capital to get us there.

Chris Cummings: How many RESI conferences have you attended previously, and when was your first event? Was ImmunoBiochem fundraising at the time?

Anton Neschadim: I have now attended three RESI conferences with the goal of raising funds every time – two in our hometown of Toronto, and the latest RESI during the JP Morgan healthcare week in San Francisco. We have closed a deal or round subsequent to each conference, and are on track to closing another round of financing following RESI in San Francisco. RESI has been extremely helpful for connecting with smart early-stage capital and learning how to better develop and tell our story to a broad range of investors. You know you have done well when you have new investors reaching out to you to learn more.

Chris Cummings: What components of RESI do you find most valuable? Do you spend most your time in partnering, or try to attend panels as well? When you participated in the Innovation Challenge, what aspects did you find beneficial?

Anton Neschadim: I tend to spend at least half of my day in one-on-one meetings, and then network with investors free-form outside of that. Panels and different tracks can help you be more targeted with the latter. I find the half-hour partnering format to be very optimal – just the right amount of time to make a connection with the investor, tell your story, answer questions, and for you to learn more about the investor’s interests and ask for feedback. The Innovation Challenge provides great exposure and is like real fundraising. It helps to have a team and to ultimately hold as many meaningful conversations as possible.

Chris Cummings: What advice can you give to other fundraising entrepreneurs attending RESI? For example, do you have any suggestions on mastering partnering, or perhaps maximizing your visibility in the Innovation Challenge?

Anton Neschadim: Visibility and being able to highlight your novelty and differentiation are paramount. What I found to be most useful is to have a team on the ground. It is great to have at least one person to move around the event, strike up conversations and bring people to your poster, while another is taking one-on-one meetings. When it comes to one-on-one meetings: register early and start requesting meetings as soon as partnering opens or even before that – spots fill up really fast. Do your research and target the right investors, avoid generic or overly long messaging, and manage time efficiently during the one-on-one meetings. The main goal is to get a second meeting or follow up.

About ImmunoBiochem

ImmunoBiochem is addressing significant unmet needs in oncology by developing highly-selective biological therapeutics. The majority of targeted biologics, which are focused on identifying and targeting unique features on the surface of cancer cells, face the challenge of tumor heterogeneity and general lack of selective tumor antigens, particularly as more potent platforms are utilized. CAR-T therapies are very exciting, with a single CAR-T cell being able to terminate from hundreds to thousands of cancer cells, but the current generation is extremely limited by very few suitable targets, such as CD19. The second generation of CAR-T therapies in the clinic will have to find a way to derive that selectivity from other mechanisms. To circumvent these challenges of surface-targeted biologics and cell therapies, ImmunoBiochem is solving this problem by combining a highly targeted and precise therapeutics platform – antibody-drug conjugates or ADCs – and non-traditional targets in the secretome of cancer cells that are amplified in the tumor microenvironment. ImmunoBiochem has defined a novel class of targets by isolating proteins with specific properties that are necessary to achieve selective and efficacious targeting of tumors with ADCs.  ImmunoBiochem was the original inventor of this technology and has tested this concept within an academic institute, and then developed a lead human antibody molecule in collaboration with the University of Toronto. Today we are supported by multiple organizations, including Johnson & Johnson Innovation (JLABS), where ImmunoBiochem is based, CCAB (the Centre for the Commercialization of Antibodies and Biologics), our key development partner and investor, OBIO, through membership and the CAAP program, and H2i at the University of Toronto.

When Raising Capital, CEOs Should Understand the LSN Value Proposition

22 Feb

By Skylar Jacobs, Business Development Manager, LSN

As Next Phase discussed two weeks ago, the world of early stage biotech and medtech investment is far less than straightforward and CEOs often have limited resources for learning where they fit into the capital landscape. In this article, we’ll look more closely at how LSN designed the LSN Investor Platform to address this problem.

Finding and Connecting with Investors that are a Fit for Your Company

LSN has found that the biggest difficulty for fundraising executives is identifying active investors that are a fit for their stage of development and product.  When raising a seed or series A financing, most executives go straight to a few brand name VCs and angel groups in their backyard, and, mistakenly, think this is going to get the job done. The reality is that fundraising is a numbers game, and there are thousands of groups across the world that are not currently known to the fundraising team, but may be a great fit for your venture. The problem is how to efficiently identify these groups, if they are a fit and, most importantly, how to reach them.

Global Matching Platform

Through this outreach, LSN has created the LSN Investor Database, giving fundraising executives the ability to generate a global target list of investors who are a fit for their company.  Like all databases, there is a front end of the active players – which is approximately half of our total network– which includes profiles of firms in active dialogue with the LSN Research Team and profiles of firms that have enough publicly available information/contact details to be listed.  The back-end of the database contains investors that have requested that LSN match them with fundraising companies but prefer not to be listed in the front end, investors we have identified but are not currently investing, and profiles that will be moved into the front end once we have enough data to justify value. The good news is that we think we have identified about 85% of the global early stage investors.  The functionality of the LSN Investor Database allows you to easily apply filters to generate a list of firms who are a fit for your company, which usually leaves about 300-500 firms as initial targets to begin initial qualification and potential interest.

Pricing

The LSN team has conducted an analysis of hundreds of successful fundraising campaigns and has determined that, on average, a start-up company can expect to spend between $70,000 to $100,000 on their fundraising efforts.  These costs include: creating and maintaining your marketing materials and web presence, business trips, conferences, partnering road trips and other miscellaneous costs.

Campaign Component
Typical Cost
Creating and maintaining your branding, messaging, marketing collateral and web presence for a year
$25,000 – $30,000
One conference per quarter, travel and expenses
$12,000 – $20,000
1-2 week road trip per quarter, two people
$10,000 – $15,000
Global target list of investors and campaign infrastructure
$10,000 – $12,000
Legal and professional fees
$10,000 – $20,000
TOTAL
$67,000 – $97,000

The LSN Investor Platform is competitively priced at $6,995 for an annual subscription to fundraising executives.  This pricing is based upon making you, the fundraiser, more effective and efficient by dramatically increasing your access to global investors that are a fit for your company’s stage of development and product. Pricing justification is that the annual subscription costs:

  • 10% of typical fundraising campaign costs
  • Approximately $25 per targeted investor profile

The LSN Research Team has done the work for you to collect details regarding exact investment interests, typical allocation size, fund vintage, company management team requirements, past investment history, and personal contact details for Partners, Directors, and C-Level Executives at each firm – information that is rarely found in other investor profiles. The price of the LSN Investor Database includes: initial identification of our client’s global target list of 300-500 investors, a consultation on your introductory marketing materials (intro email and deck), campaign outreach advice, and email alerts including updates of investors added to the platform who are a fit for your company.  Additionally, the LSN Investor Platform includes an export function that provides startup CEOs with data that can be imported into a CRM system to manage outreach and track the progress of every investor relationship.  LSN has already integrated with SalesForce.com to make this process seamless for our clients.  In total, LSN offers a complete package for fundraising executives to ensure they have the strategy and investor targets necessary to conduct a successful capital raise.

The Redefining Early Stage Investments Conference Series

In addition to the LSN Investor Platform, the RESI Conference is another tool provided by LSN for fundraising CEOs. The RESI conference allows entrepreneurs to meet face-to-face with up to 16 relevant investors in one day and begin to develop a personal relationship with them. Subscribers of the LSN Investor Platform have a powerful tool that allows them dig into the investors’ profile prior to the meeting to understand the investors’ interests and preferences, greatly increasing the quality of an intro discussion and making the best use of their face-time. Using the LSN Investor Platform and RESI conference in parallel creates a tremendous value for any fundraising CEO in the early-stage life science space by not only providing the connections, but also by facilitating face-to-face interactions.

In Summary

LSN estimates that approximately 250 clients who read our CEO’s book, The Life Science Executive’s Fundraising Manifesto, purchased the database, and participated in the RESI Conference Series have raised upwards of 350 million dollars.  LSN’s value add to a fundraising CEO and scientist/entrepreneur is equivalent to 5 years’ work by 6 LSN research analysts, curating your Global Target List (GTL), which is at least 50% of the effort of raising capital – finding investors that are a fit for your stage of development and product.

The personal connection between the LSN research team and an investment firm allows LSN to capture and utilize a unique flow of information and provides an unmatched tool for fundraising CEOs to understand the players in their space, their nuanced preferences/strategies and a way to begin a dialogue with them. No other service or data provider comes close to the focused, high touch, relationship-oriented nature of data collection and maintenance.

Hot Investor Mandate 1: Global VC Invests Up to $10M in Novel Software-Based Healthcare Technologies with Focus in North America

22 Feb

A venture capital firm with a global presence invests in several verticals with the core interest being in scalable, breakthrough technologies. Initial investments may range from $100k – $1M, with up to $10M being invested over the life of the investment, in the form of convertible notes or straight equity. The firm will lead investments or co-invest as a syndicate. The firm will invest in companies on a global basis but is focused on companies in the U.S. and Canada. The partners and advisors of the fund look to add value to portfolio companies through an extensive international network and strong technical expertise.

The firm is generally agnostic to industry and is most interested in unique/novel technologies, with a special interest in AI and blockchain solutions in the healthcare space. While the group is primarily interested in software-based technologies, whether in drug discovery, enterprise software, digital health, etc., medical devices that do not require a traditional regulatory pathway (510(k) or PMA) and that have a core software component will also be considered.

The firm has no strict company or management team requirements and looks to mentor companies/management teams. The firm does not require a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Venture Arm of Large Health Insurance Provider Invests Broadly in Medtech, Diagnostics, and Digital Health with Strong Strategic Value

22 Feb

A wholly-owned venture arm subsidiary of one of the largest health insurers makes strategic investments in healthcare-related innovations that will improve the quality of care and enhance the overall healthcare experience for consumers and providers. 3 important considerations are strategic value, financial return, and improvement in health outcomes. The firm typically participates in Series B or post-Series A bridge rounds. The firm entertains domestic and international opportunities.

The firm invests broadly across healthcare. Recent investments include a lung cancer diagnostics company, a specialty pharmacy company that simplifies medication management, and a behavioral health care management company. The firm expects companies to be past the proof-of-concept stage with demonstration of some traction.

The firm has no specific requirements and can work with all kinds of management teams. The firm is open to both leading and co-investing in financing rounds. The firm may take a board seat when applicable.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Life Sciences VC Arm of Large Czech Financial Group Seeks Early-Stage Investment Opportunities in All Sectors

22 Feb

An investment arm of a large, Czech Republic-based financial group that manages 10 sub-funds that total to $400M AUM, has a $22M fund through which the firm actively invests in early-stage life-science companies. The firm prefers to act as the first institutional investor – i.e. it deploys around $250 to $350,000 as initial investment and then provides follow-on investments for companies that achieve a number of milestones. The firm will consider opportunities globally, but mainly focuses its activities in North America and Europe.

The fund is sector agnostic and will consider all innovative technologies within the areas of therapeutics, medical devices, diagnostics, and healthcare IT. About 1/3 of the fund is dedicated to digital health technologies with special interest in the area of mental health. While the fund is mostly indication agnostic, it tends to avoid the over-crowded indications such as oncology/immune-oncology.

The firm is an active investor and takes a dedicated role in its portfolio of companies, providing them with resources and expertise to support company growth. The firm seeks to work with experienced management teams that are working on technology with strong market potential. The firm prefers to act as the lead investor but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Seed-Stage Venture Fund Invests in Ontario-Based Life Science Companies with Strongest Interest in Healthcare IT/Digital Health

22 Feb

A seed-stage venture capital fund that seeks to invest in Ontario-based companies operating in the cleantech, information and communication technology, life science and healthcare sectors. The firm is based out of Toronto, Canada and has been investing for over 10 years. The fund is sector-agnostic and invests in several verticals including but not limited to IT, healthcare, and cleantech. The fund makes investments up to $500K in Ontario-based startups, and typically targets 15 deals per year. The fund will invest with VCs and other institutional investors.

The fund is a generalist fund, but within the healthcare space, the focus is on healthcare IT and digital health companies whose core technology is software, whether it be enterprise solutions or more consumer-facing or point of care technologies. Traditional medical devices, biopharma/therapeutics and other life science platform technologies will be also be considered.

The firm requires the company be legally company incorporated and likes to see a formal management structure in place by the time of closing an investment. It’s not necessary that the company have revenues, but the company must have a clear understanding of their path to market and an execution strategy in place that will allow them to move faster than competitors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.